查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1590812

胃腸道藥物市場：按分類、疾病類型、給藥途徑和最終用戶分類 - 全球預測 2025-2030

Gastrointestinal Drugs Market by Drug Category (Acid Neutralizers, Anti-Inflammatory, Antiemetic & Antinauseants), Disease Type (Gastroesophageal Reflux Disorder, Irritable Bowel Syndrome), Route of Administration, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年胃腸道藥物市場價值為541.8億美元，預計2024年將達到572.7億美元，複合年成長率為5.78%，到2030年將達到803.1億美元。

胃腸道藥物市場廣泛集中於治療各種消化器官系統問題的藥物，包括潰瘍、發炎發炎性腸道疾病腸道疾病、大腸激躁症和胃食道逆流症。該市場的定義是需要這些藥物來控制全球數百萬人的症狀並改善生活品質。應用範圍涵蓋醫院、診所和家庭護理機構使用的處方藥和非處方藥，最終用途為成人和兒童群體。根據市場洞察，胃腸道疾病發病率的增加、老年人口的增加以及藥物配方的進步正在推動顯著的成長軌跡。然而，嚴格的監管要求、高昂的藥物開發成本和潛在的副作用等挑戰是市場擴張的主要障礙。此外，COVID-19 大流行改變了醫療保健分配的優先順序，影響了非緊急護理的重點和資金籌措。有大量商機可望滿足治療功效和患者依從性方面未滿足的需求，例如生技藥品和生物相似藥的開發、個人化醫療方法以及奈米技術等新型藥物輸送系統。為了利用這些機會，公司應該投資研發，並專注於既有效又副作用最小的創新解決方案。您還應該考慮建立策略聯盟和合作，以加強產品平臺和市場滲透。然而，市場相關人員必須保持對競爭格局的認知，其特徵是競爭激烈和技術快速發展。創新和研究的最佳領域包括探索微生物組療法和人工智慧驅動的患者分層工具，以實現量身定做的治療計劃。市場動態的動態本質需要不斷創新來應對新挑戰，同時最大限度地提高世界各地患者的治療價值和可近性。

主要市場統計
基準年[2023] 541.8億美元
預測年份 [2024] 572.7億美元
預測年份 [2030] 803.1億美元
複合年成長率（%） 5.78%

市場動態：揭示快速發展的胃腸道藥物市場的關鍵市場洞察

胃腸道藥物市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 老年人口增加，生活方式飲食習慣改變
    • 生技藥品的發展和直腸相關疾病的增加
    • 藥物開發和意識提高
  • 市場限制因素
    • 與藥物相關的副作用
  • 市場機會
    • 加強藥物開發的研究和開發活動
    • 治療過程中的技術進步
  • 市場挑戰
    • 缺乏對發炎性腸道疾病腸道疾病和大腸激躁症等疾病的永久性治療方法；

波特五力：駕馭胃腸道藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解胃腸道藥物市場的外部影響

外部宏觀環境因素對胃腸道藥物市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解胃腸道藥物市場競爭狀況

對胃腸道藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣胃腸道藥物市場供應商績效評估

FPNV定位矩陣是評估胃腸道藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製胃腸道藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對胃腸道藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 老年人口增加、生活方式和飲食習慣改變
      • 生物製藥的開發與直腸相關疾病的增加
      • 藥物開發和意識提高
    • 抑制因素
      • 與藥物相關的副作用
    • 機會
      • 加強藥物開發的研究和開發活動
      • 治療過程中的技術進步
    • 任務
      • 對於發炎性腸道疾病腸道疾病和大腸激躁症等疾病，沒有永久性的治療方法。
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 胃腸道藥物市場（依藥物類別）

  • 酸中和劑
  • 發炎（藥
  • 止吐和鎮痛藥
  • 生物製藥
  • 瀉藥/止瀉藥

第7章胃腸道藥物市場：依疾病類型

  • 胃食道逆流症
  • 大腸激躁症

第8章胃腸道藥物市場：依給藥途徑

  • 口服
  • 胃腸外的
  • 直腸

第9章胃腸道藥物市場：依最終使用者分類

  • 醫院藥房
  • 零售藥房

第10章美洲胃腸道藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太胃腸道藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲/中東/非洲胃腸道藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Eisai Co., Ltd.
  • Eli Lilly & Co.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Novo Nordisk A/S
  • Sanofi SA
  • SFJ Pharmaceuticals Group
  • SRS Life Sciences Pte. Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Industries Limited
  • ZERIA Pharmaceutical Co.,Ltd.
Product Code: MRR-434CCDA051D0

The Gastrointestinal Drugs Market was valued at USD 54.18 billion in 2023, expected to reach USD 57.27 billion in 2024, and is projected to grow at a CAGR of 5.78%, to USD 80.31 billion by 2030.

The scope of the gastrointestinal drugs market involves a broad focus on medications designed to treat a variety of digestive issues ranging from ulcers, inflammatory bowel disease, irritable bowel syndrome, to gastroesophageal reflux disease. This market is defined by the necessity of these medications to manage symptoms and improve the quality of life for millions of individuals worldwide. Application spans across prescriptions and over-the-counter medications used in hospitals, clinics, and homecare settings, with the end-use scope extending to both adult and pediatric populations. Market insights reveal a significant growth trajectory fueled by rising incidences of gastrointestinal disorders, increasing geriatric populations, and advancements in drug formulations. However, challenges such as stringent regulatory requirements, high costs of drug development, and potential side effects pose significant impediments to market expansion. Moreover, the COVID-19 pandemic has shifted priorities in healthcare allocations, impacting focus and funding toward non-urgent treatments. Opportunities abound in the development of biologics and biosimilars, personalized medicine approaches, and novel drug delivery systems like nanotechnology, which are expected to cater to unmet needs in treatment efficacy and patient compliance. To capitalize on these opportunities, companies should invest in R&D, focusing on innovative solutions that combine efficacy with minimal adverse reactions. They should also consider forging strategic alliances and collaborations to enhance their product pipeline and market reach. However, market players should remain cognizant of the competitive landscape characterized by high rivalry and the fast pace of technological evolution. The best areas for innovation and research include exploration into microbiome therapeutics and AI-driven patient stratification tools, allowing for tailored treatment plans. The nature of the gastrointestinal drugs market is dynamic, demanding continual innovation to address emerging challenges while maximizing therapeutic value and accessibility for patients globally.

KEY MARKET STATISTICS
Base Year [2023] USD 54.18 billion
Estimated Year [2024] USD 57.27 billion
Forecast Year [2030] USD 80.31 billion
CAGR (%) 5.78%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gastrointestinal Drugs Market

The Gastrointestinal Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing geriatric population, changing lifestyles and eating habits
    • Development in biologics and a rising number of rectal related diseases
    • Drug development and rising awareness
  • Market Restraints
    • Side effects associated with the drugs
  • Market Opportunities
    • R&D activities to enhance drug development
    • Technological advancements in the treatment process
  • Market Challenges
    • Unavailable permanent cure for diseases such as inflammatory bowel disease and Irritable bowel syndrome

Porter's Five Forces: A Strategic Tool for Navigating the Gastrointestinal Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gastrointestinal Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gastrointestinal Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gastrointestinal Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gastrointestinal Drugs Market

A detailed market share analysis in the Gastrointestinal Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gastrointestinal Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gastrointestinal Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gastrointestinal Drugs Market

A strategic analysis of the Gastrointestinal Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gastrointestinal Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bayer AG, Boehringer Ingelheim GmbH, Eisai Co., Ltd., Eli Lilly & Co., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Novo Nordisk A/S, Sanofi S.A., SFJ Pharmaceuticals Group, SRS Life Sciences Pte. Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Limited, and ZERIA Pharmaceutical Co.,Ltd..

Market Segmentation & Coverage

This research report categorizes the Gastrointestinal Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Category, market is studied across Acid Neutralizers, Anti-Inflammatory, Antiemetic & Antinauseants, Biologics, and Laxatives & Anti-diarrheal.
  • Based on Disease Type, market is studied across Gastroesophageal Reflux Disorder and Irritable Bowel Syndrome.
  • Based on Route of Administration, market is studied across Oral, Parenteral, and Rectal.
  • Based on End User, market is studied across Hospital Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing geriatric population, changing lifestyles and eating habits
      • 5.1.1.2. Development in biologics and a rising number of rectal related diseases
      • 5.1.1.3. Drug development and rising awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Side effects associated with the drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. R&D activities to enhance drug development
      • 5.1.3.2. Technological advancements in the treatment process
    • 5.1.4. Challenges
      • 5.1.4.1. Unavailable permanent cure for diseases such as inflammatory bowel disease and Irritable bowel syndrome
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gastrointestinal Drugs Market, by Drug Category

  • 6.1. Introduction
  • 6.2. Acid Neutralizers
  • 6.3. Anti-Inflammatory
  • 6.4. Antiemetic & Antinauseants
  • 6.5. Biologics
  • 6.6. Laxatives & Anti-diarrheal

7. Gastrointestinal Drugs Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Gastroesophageal Reflux Disorder
  • 7.3. Irritable Bowel Syndrome

8. Gastrointestinal Drugs Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral
  • 8.4. Rectal

9. Gastrointestinal Drugs Market, by End User

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Retail Pharmacies

10. Americas Gastrointestinal Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Gastrointestinal Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Gastrointestinal Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Bayer AG
  • 3. Boehringer Ingelheim GmbH
  • 4. Eisai Co., Ltd.
  • 5. Eli Lilly & Co.
  • 6. GlaxoSmithKline PLC
  • 7. Johnson & Johnson Services, Inc.
  • 8. Novo Nordisk A/S
  • 9. Sanofi S.A.
  • 10. SFJ Pharmaceuticals Group
  • 11. SRS Life Sciences Pte. Ltd.
  • 12. Sun Pharmaceutical Industries Limited
  • 13. Takeda Pharmaceutical Company Limited
  • 14. Teva Pharmaceuticals Industries Limited
  • 15. ZERIA Pharmaceutical Co.,Ltd.

LIST OF FIGURES

  • FIGURE 1. GASTROINTESTINAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GASTROINTESTINAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GASTROINTESTINAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. GASTROINTESTINAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GASTROINTESTINAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GASTROINTESTINAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ACID NEUTRALIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ANTIEMETIC & ANTINAUSEANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY LAXATIVES & ANTI-DIARRHEAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISORDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY IRRITABLE BOWEL SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RECTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GASTROINTESTINAL DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GASTROINTESTINAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY DRUG CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM GASTROINTESTINAL DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. GASTROINTESTINAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. GASTROINTESTINAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023